Fulcrum Therapeutics (FULC) Competitors $3.77 -0.11 (-2.84%) (As of 12:09 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends FULC vs. PRTA, TYRA, CRGX, AVXL, CRON, RLAY, CGEM, TRDA, TECX, and DNTHShould you be buying Fulcrum Therapeutics stock or one of its competitors? The main competitors of Fulcrum Therapeutics include Prothena (PRTA), Tyra Biosciences (TYRA), CARGO Therapeutics (CRGX), Anavex Life Sciences (AVXL), Cronos Group (CRON), Relay Therapeutics (RLAY), Cullinan Therapeutics (CGEM), Entrada Therapeutics (TRDA), Tectonic Therapeutic (TECX), and Dianthus Therapeutics (DNTH). These companies are all part of the "pharmaceutical products" industry. Fulcrum Therapeutics vs. Prothena Tyra Biosciences CARGO Therapeutics Anavex Life Sciences Cronos Group Relay Therapeutics Cullinan Therapeutics Entrada Therapeutics Tectonic Therapeutic Dianthus Therapeutics Fulcrum Therapeutics (NASDAQ:FULC) and Prothena (NASDAQ:PRTA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, community ranking, institutional ownership, analyst recommendations, risk, profitability and earnings. Which has higher valuation and earnings, FULC or PRTA? Fulcrum Therapeutics has higher earnings, but lower revenue than Prothena. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFulcrum Therapeutics$2.81M72.37-$97.33M-$0.31-12.16Prothena$91.37M8.41-$147.03M-$2.48-5.76 Does the media prefer FULC or PRTA? In the previous week, Fulcrum Therapeutics had 6 more articles in the media than Prothena. MarketBeat recorded 7 mentions for Fulcrum Therapeutics and 1 mentions for Prothena. Prothena's average media sentiment score of 1.89 beat Fulcrum Therapeutics' score of 0.99 indicating that Prothena is being referred to more favorably in the news media. Company Overall Sentiment Fulcrum Therapeutics Positive Prothena Very Positive Does the MarketBeat Community favor FULC or PRTA? Prothena received 507 more outperform votes than Fulcrum Therapeutics when rated by MarketBeat users. Likewise, 70.43% of users gave Prothena an outperform vote while only 61.25% of users gave Fulcrum Therapeutics an outperform vote. CompanyUnderperformOutperformFulcrum TherapeuticsOutperform Votes9861.25% Underperform Votes6238.75% ProthenaOutperform Votes60570.43% Underperform Votes25429.57% Do institutionals & insiders believe in FULC or PRTA? 89.8% of Fulcrum Therapeutics shares are owned by institutional investors. Comparatively, 97.1% of Prothena shares are owned by institutional investors. 4.1% of Fulcrum Therapeutics shares are owned by insiders. Comparatively, 28.1% of Prothena shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is FULC or PRTA more profitable? Fulcrum Therapeutics has a net margin of 0.00% compared to Prothena's net margin of -98.86%. Fulcrum Therapeutics' return on equity of -7.31% beat Prothena's return on equity.Company Net Margins Return on Equity Return on Assets Fulcrum TherapeuticsN/A -7.31% -6.74% Prothena -98.86%-24.19%-20.59% Do analysts prefer FULC or PRTA? Fulcrum Therapeutics currently has a consensus price target of $9.33, suggesting a potential upside of 147.57%. Prothena has a consensus price target of $61.86, suggesting a potential upside of 333.17%. Given Prothena's stronger consensus rating and higher possible upside, analysts clearly believe Prothena is more favorable than Fulcrum Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fulcrum Therapeutics 1 Sell rating(s) 6 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20Prothena 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71 Which has more volatility & risk, FULC or PRTA? Fulcrum Therapeutics has a beta of 2.14, meaning that its stock price is 114% more volatile than the S&P 500. Comparatively, Prothena has a beta of 0.09, meaning that its stock price is 91% less volatile than the S&P 500. SummaryProthena beats Fulcrum Therapeutics on 10 of the 18 factors compared between the two stocks. Ad Crypto Swap Profits[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Fulcrum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FULC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FULC vs. The Competition Export to ExcelMetricFulcrum TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$203.35M$6.73B$5.20B$8.97BDividend YieldN/A7.94%5.23%4.04%P/E Ratio-12.164.7285.7113.39Price / Sales72.37352.931,469.4286.49Price / CashN/A22.8835.2935.09Price / Book0.995.604.914.96Net Income-$97.33M$151.32M$117.36M$224.10M7 Day Performance6.20%3.14%2.75%2.01%1 Month Performance17.45%-1.67%1.71%9.79%1 Year Performance-24.45%31.88%36.01%29.97% Fulcrum Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FULCFulcrum Therapeutics3.3511 of 5 stars$3.77-2.8%$9.33+147.6%-22.2%$203.35M$2.81M-12.16100Short Interest ↓PRTAProthena1.9907 of 5 stars$15.33-5.4%$61.86+303.5%-57.0%$824.91M$91.37M-6.54173Positive NewsTYRATyra Biosciences2.7187 of 5 stars$16.05+2.4%$31.00+93.1%+36.6%$812.18MN/A-9.7420Positive NewsCRGXCARGO Therapeutics1.8452 of 5 stars$17.44-4.1%$30.33+73.9%+9.9%$802.73MN/A-4.15116AVXLAnavex Life Sciences3.7203 of 5 stars$9.43-0.3%$43.00+356.0%+23.1%$799.66MN/A-18.9240CRONCronos Group2.3149 of 5 stars$2.08flat$3.00+44.2%-1.4%$795.18M$87.24M-16.00356RLAYRelay Therapeutics3.7829 of 5 stars$4.73+0.6%$21.22+348.7%-46.3%$791.72M$10.01M-1.80304Positive NewsCGEMCullinan Therapeutics2.205 of 5 stars$13.53+0.6%$31.67+134.0%+52.1%$787.83M$18.94M-4.7430News CoveragePositive NewsTRDAEntrada Therapeutics1.9959 of 5 stars$19.94+0.3%$24.00+20.4%+51.6%$746.16M$215.23M12.49110Positive NewsGap UpTECXTectonic Therapeutic3.2744 of 5 stars$49.81+0.1%$72.25+45.1%N/A$734.85MN/A-8.45120Short Interest ↑DNTHDianthus Therapeutics1.9137 of 5 stars$24.28+1.2%$46.43+91.2%+128.0%$718.69M$2.83M-9.6080Short Interest ↑Positive News Related Companies and Tools Related Companies PRTA Competitors TYRA Competitors CRGX Competitors AVXL Competitors CRON Competitors RLAY Competitors CGEM Competitors TRDA Competitors TECX Competitors DNTH Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:FULC) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fulcrum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fulcrum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FULC Stock Alerts